A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 700 participants.
Also called NCT06679946
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 700 participants
- Sponsor
- Registry
-
NCT06679946 -
2024-516568-27
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Italy, Netherlands, Norway, Portugal, South Korea, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06679946. Allocation not applicable; no masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2028-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug)
- Vutrisiran
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct06679946- Content hash
8a9a0da902607392bb9f4ba01638b76fbacf2e2d2121260ec127c699f58668c6